home > drugs a-z list > pegasys (peginterferon alfa-2a) drug center

Recommended Topic Related To:

Pegasys

Hepatitis C infection facts

  • HCV is one of several viruses that cause hepatitis (inflammation of the liver).
  • Up to 85% of individuals who are initially (acutely) infected with HCV will fail to eliminate the virus and will become chronically infected.
  • HCV is spread most commonly through inadvertent exposure to infected blood. Intravenous drug abuse is the most common mode of transmission. The risk of acquiring HCV through sexual contact is low.
  • Generally, patients do not develop symptoms of chronic infection with HCV until they have extensive scarring of the liver (cirrhosis). Some individuals, however, may have fatigue and other non-specific symptoms in the absence of cirrhosis. A minority of patients with HCV have symptoms from organs outside of the liver.
  • In the U.S., Infection with HCV is the most common cause of chronic hepatitis and the most common reason for liver transplantation.
  • ...

Pegasys

font size

Pegasys Drug Center

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Pegasys Prescribing Information: Indications & Dosage

Chronic Hepatitis C

PEGASYS, peginterferon alfa-2a, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C (CHC) virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Efficacy has been demonstrated in subjects with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and in subjects with clinically stable HIV disease and CD4 count greater than 100 cells/mm3.

The following points should be considered when initi...

Read the complete drug monograph for Pegasys »

What is Patient information?

Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.

Pegasys Patient Information: Side Effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Stop using peginterferon alfa-2a and call your doctor at once if you have any of these serious side effects:

  • confusion, severe depression, thoughts of hurting yourself or others;
  • unusual anxiety, aggression, or unusual thoughts or behaviors;
  • sudden numbness, weakness, or loss of balance or coordination;
  • fever, chills, body aches, flu symptoms;
  • easy bruising or ...

Read the complete patient information for Pegasys »

What is Consumer information?

A concise overview of the drug for the patient or caregiver from First DataBank.

Pegasys Consumer Information: Uses

Peginterferon alfa-2a is used alone or in combination with ribavirin to treat chronic hepatitis C, a viral infection of the liver. It is also used to treat chronic hepatitis B infection.

This medication reduces the amount of hepatitis C virus in the body and helps the body's immune system fight the infection. It is not known if peginterferon can cure hepatitis C virus infections (permanently eliminate the virus from your body). It is also not known if this drug can prevent you from passing the virus to others. Practice "safe sex" (including the use of latex condoms) to lower the risk of pas...

Read the complete consumer information for Pegasys »

What is Pegasys Consumer Information?

Warnings - Uses - How to Use - Side Effects - Precautions - Drug Interactions and More

Pegasys - User Reviews

Pegasys User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Pegasys sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Living Better

Find the secrets to longer life.